US equities |
SPCX $167.06 ▲+5.10% NVDA $236.37 ▲+1.03% MU $1,064.54 ▼-0.96% TSLA $378.45 ▲+2.12% MSFT $525.06 ▲+1.45% SNDK $1,709.58 ▼-0.61% INTC $117.40 ▼-1.62% META $743.21 ▲+2.08%
FinancialContent

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

22.66 -0.54 (-2.35%)
Delayed Quote Updated: 12:24 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug ↗
The results bode well for an ongoing Phase 3 study examining cardiovascular outcomes. 
Via Investor's Business Daily
News headline image
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma ↗
 
Via Benzinga
News headline image
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study ↗
The company's combination treatment lowered LDL cholesterol by about 50% over 84 days. 
Via Investor's Business Daily
News headline image
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Expert Ratings For NewAmsterdam Pharma ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside ↗
Needham initiates coverage on NewAmsterdam Pharma with a Buy rating, highlighting the potential of its cholesterol-lowering drug, obicetrapib. 
Via Benzinga
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results ↗
NewAmsterdam Pharma announced positive topline results from the Phase 3 BROOKLYN trial for obicetrapib, showing a significant LDL-C reduction in HeFH patients. The stock fell 8.35% despite the success,... 
Via Benzinga
News headline image
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations ↗
The company is hoping to use a new mechanism to lower "bad" LDL cholesterol. 
Via Investor's Business Daily
News headline image
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
Company to host conference call on Monday, July 29 at 8:30 a.m. ET 
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
-- Company expects to report topline data in the first quarter of 2025 -- 
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >